+

WO1999058681A2 - Cellules de plantes transgeniques exprimant un peptide e2f vegetal recombinant - Google Patents

Cellules de plantes transgeniques exprimant un peptide e2f vegetal recombinant Download PDF

Info

Publication number
WO1999058681A2
WO1999058681A2 PCT/EP1999/003158 EP9903158W WO9958681A2 WO 1999058681 A2 WO1999058681 A2 WO 1999058681A2 EP 9903158 W EP9903158 W EP 9903158W WO 9958681 A2 WO9958681 A2 WO 9958681A2
Authority
WO
WIPO (PCT)
Prior art keywords
plant
protein
peptide
sequence
seq
Prior art date
Application number
PCT/EP1999/003158
Other languages
English (en)
Other versions
WO1999058681A3 (fr
Inventor
Crisanto Gutierrez-Armenta
Qi Xie
Elena Ramirez Parra
Original Assignee
Consejo Superior De Investigaciones Cientificas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior De Investigaciones Cientificas filed Critical Consejo Superior De Investigaciones Cientificas
Priority to AU38280/99A priority Critical patent/AU3828099A/en
Priority to JP2000548472A priority patent/JP2002514423A/ja
Priority to CA002327546A priority patent/CA2327546A1/fr
Priority to EP99920859A priority patent/EP1084249A2/fr
Publication of WO1999058681A2 publication Critical patent/WO1999058681A2/fr
Publication of WO1999058681A3 publication Critical patent/WO1999058681A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8261—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
    • Y02A40/10—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in agriculture
    • Y02A40/146—Genetically Modified [GMO] plants, e.g. transgenic plants

Definitions

  • the present invention related Iff ⁇ flgieic acid sequences encoding plant E2F proteins or functional variants thereof, including peptides, and the use of said sequences for controlling the plant cell cycle stage and or its body architecture.
  • the invention also provides plant E2F proteins and peptides useful in producing antibodies, and provides nucleic acids suitable for use in detection and amplification of plant E2F peptides and proteins.
  • Cell cycle progression is the result of a complex and highly regulated network.
  • Crucial for the correct passage of the cell through the different cell cycle stages is the strict regulation of the transcriptional activity of certain genes, e. g., S-phase specific genes (reviewed in Nevins, 1992; Helin, 1998).
  • E2F family of transcription factors play this pivotal role in transcriptional regulation at the Gl/S transition. Their concerted action is thought to modulate the expression of cell cycle regulatory genes such as cdc2, cyclins A and E, Rb, pi 07 and E2F-1, and genes involved in DNA metabolism, such as the dihydrofolate reductase, thymidine kinase, thymidylate synthase, DNA polymerase ⁇ , ORC1 and CDC6 (reviewed in Nevins, 1992; Helin, 1998).
  • Rb retinoblastoma
  • pi 07 and pi 30 proteins through the formation of complexes between the different E2F members and pocket proteins (reviewed in Weinberg, 1995).
  • Rb is targeted to E2F-responsive gene promoters and inhibits transcription through interaction with adjacent factors, as recently shown for histone deacetylase (Brehm et al., 1998; Magnaghi-Jaulin et al., 1998).
  • other systems such as plants, which have unique properties in terms of cell growth and plasticity, body organization and development, the factors involved in cell cycle regulation, in particular at the Gl/S transition, and their mechanism of action are significantly less understood.
  • S-phase specific transcription factors are possible in plant cells, but their molecular nature is not known yet. In particular, whether they have any structural and/or functional similarity to the animal E2F family of transcription factors is one of the important questions that still needs to be answered. In addition, it is known that the activity of S-phase specific protein kinases increases during early stages of endosperm development (Grafi and Larkins, 1995).
  • Plant Rb-like protein has some features in common with its human counterpart, including the presence of a residue homologous to C607 of human Rb required for its activity and its ability to interact with the three plant D-type cyclins in a LXCXE-dependent manner (Huntley et al., 1998). Furthermore, quite interestingly, when plant Rb is expressed in human cells, it is able to repress an E2F-responsive promoter (Huntley et al., 1998). Altogether, these studies predict the existence of S- phase specific transcription factors (STF) in plant cells (Xie et al., 1995), perhaps related to the E2F family of transcription factors found in animal cells. However, the identification of E2F-like transcription factors in plants has been elusive since studies using heterologous probes derived from human E2F cDNA clones have been unsuccessful.
  • STF S- phase specific transcription factors
  • the present inventors have now isolated, cloned and characterized cDNA encoding a plant protein which interacts with plant Rb in the yeast two-hybrid system. They have established that this cDNA clone encodes a plant E2F family member (TmE2F) with amino acid homology to animal E2F proteins.
  • TmE2F plant E2F family member
  • the inventors have further determined that, surprisingly, plants appear to contain a single E2F member with a domain organisation similar to that of human E2F, including a highly conserved DNA binding domain, a less conserved dimerization domain and relatively unrelated transactivation and Rb-binding domains. Interestingly, its Rb-binding domain contains amino acid residues different from those found in animal E2F but showing conservation of their hydrophobic or charged properties.
  • a "functional variant" of a peptide or protein is a polypeptide the amino acid sequence of which can be derived from the amino acid sequence of the original peptide or protein by the substitution, deletion and/or addition of one or more amino acid residue in a way that, in spite of the change in the amino acid sequence, the functional variant retains at least a part of at least one of the biological activities of the original protein that is detectable for a person skilled in the art.
  • a functional variant is generally at least 50% homologous, advantageously at least 70% homologous and even more advantageously at least 90% homologous to the protein from which it can be derived.
  • the amino acid sequence of the functional variant is 50% identical, more preferably 70% identical and most preferably 90% identical to the peptide or protein. Any functional part of a protein or a variant thereof is also termed functional variant.
  • Algorithms and software suitable for use in aligning amino acid or nucleotide sequences for comparison and calculation of sequence homology or identity will be known to those skilled in the art.
  • Significant examples of such tools are the Pearson and Lipman search based FAST and BLAST programs. Details of these may be found in Altschul et al (1990), J. Mol. Biol. 215: 403-10; Lipman D J and Pearson W R (1985) Science 227, pl435-41.
  • Publically available details of BLAST may be found on the internet at 'http://www.ncbi. nlm.nih.gov/BLAST/blast-help.html'.
  • homology and identity percentages can be ascertained using commercially or publically available software packages incorporating, for example, FASTA and BLASTn software or by computer servers on the internet.
  • the former are the GCG program package (Devereux et al Nucelic Acids Research (1984) 12 (1): 387) and the Bestfit program (Wisconsin Sequence Analysis Package, eg. Version 8 for Unix or IBM equivalent, Genetics Computer Group, University Researh Park, 575 Science Drive, Madison, WI 53711 ) which uses the local homology algorithm of Smith and Waterman, Advances in Mathematics 2:482-489 (1981).
  • Genbank see http://www.ncbi.nlm.nih.gov/BLAST
  • EMBL see http://www.embl-heidelberg.de/Blast2
  • identity is meant that the stated percentage of the claimed amino acid sequence or base sequence is to be found in the reference sequence in the same relative positions when the sequences are optimally aligned, notwithstanding the fact that the sequences may have deletions or additions in certain positions requiring introduction of gaps to allow alignment of the highest percentage of amino acids or bases.
  • sequence are aligned by using 20 or less gaps, ie. the total number of gaps introduced into the two sequences when added together is 20 or less, more preferably 10 or less.
  • the length of such gaps is not of particular importance as long as one or other of the two defined E2F activities is retained but generally will be no more than 50, and preferably no more than 10 amino acids, or 150 and preferably no more than 30 bases.
  • Convenient parameters for BLAST searches are the default values, ie. for EMBL Advanced Blast2: Blastp Matrix BLOSUMS 62, Filter default, Echofilter X, Expect 10, Cutoff default, Strand both, Descriptions 50, Alignments 50.
  • BLASTn defaults are again preferably used.
  • GCG Wisconsin Package defaults are Gap Weight 12, Length weight 4.
  • the term "overproducing" is used herein in the most general sense possible.
  • a special type of molecule is said to be "overproduced” in a cell if it is produced at a level significantly and detectably higher (e.g. 20%) higher) than natural level.
  • Overproduction of a molecule in a cell can be achieved via both traditional mutation and selection techniques and genetic manipulation methods .
  • ectopic expression is used herein to designate a special realisation of overproduction in the sense that, for example, an ectopically expressed peptide or protein is produced at a spatial point of a plant where it is naturally not at all (or not detectably) expressed, that is, said peptide or protein is overproduced at said point.
  • Particularly preferred ectopic expression is that which only reaches functional levels in a selected tissue and does not do so throughout the plant. This preferred ectopic expression is in contrast to constitutive expression.
  • the term 'underproducing' is intended to cover production of polypeptide or mRNA at a level significantly lower than the natural level (eg. 20%) or more lower), particularly to undetectable levels.
  • a method of controlling plant growth and/or cellular DNA replication and/or cell cycle progression, differentiation and development comprising increasing or decreasing E2F activity in a plant cell through expression of a recombinant E2F peptide or protein in that cell.
  • the method is characterised in that the plant E2F activity comprises one or both of (i) the ability to bind plant Retinoblastoma protein and (ii) the ability to bind to E2F transcription factor binding sites in plant DNA.
  • This may include steps of altering the plant E2F protein level, subcellular localisation, DNA-binding activity, the protein-protein binding activity, transactivation properties, and/or the E2F-Rb- binding activity.
  • the plant E2F may be modified alone and/or in combination with a modification of the levels or activity of plant Rb.
  • the ability to bind to the E2F transcription factor binding sites in plant DNA need not necessarily lead to transcription activation. Inhibition of such activation can also be provided using the present invention.
  • the method may be used to alter plant cell or organ shape, and it may alter cell proliferation characteristics such as to increase plant cell or plant organ size.
  • the method may also increase or decrease expression of other proteins.
  • the present invention provides an isolated, enriched, cell free and/or recombinantly produced protein or peptide, capable of altering E2F activity in a plant cell, characterised in that it has one or both E2F activities in plants selected from (i) the ability to bind plant Retinoblastoma protein and (ii) the ability to bind to E2F transcription factor binding sites in plant DNA wherein the protein or peptide comprises one or both amino acid sequences selected from the following domains of SEQ ID No 6:
  • the peptide or protein comprises at least 50% of the contiguous sequence and still more preferably at least 70%> thereof. Most preferably the peptide or protein comprises SEQ ID No 6 or a functional variant thereof.
  • Preferred variants are those in which the domain (a) has been deleted or in which it is inactivated, eg. by Site directed mutagenesis.
  • peptides or proteins of the invention are characterised in that they are of SEQ ID No 6 or variant but modified such that the amino acid sequence SEQ ID No 2 is mutated such that its ability to bind Rb protein is reduced from that of the native sequence of SEQ ID No 2 or abolished completely therefrom, whereby the peptide is capable of acting as an E2F protein without being restricted by Rb binding
  • peptides or proteins of SEQ ID No 6 or functional variants thereof are provided that do not have the transinducing properties of the protein of SEQ ID No 6, these preferably having mutations or deletions or insertions in the transinducing domain of SEQ ID No 6 in the C-terminal.
  • peptides or proteins of reduced length for example 16 to 300, more preferably from 16 to 100 amino acids.
  • peptides or proteins are characterised in that they comprise an amino acid sequence of SEQ ID No 2 or a functional variant thereof. Still more preferred are peptides or proteins of the invention that are characterised in that they further comprises a sequence of SEQ ID No 7, that being of sequence
  • Useful variants of such proteins are those in which the NLS of SEQ ID No 7 is modified, eg. by site directed mutagenesis, eg using PCR, such that the peptide does not localise in the nucleus.
  • peptides or proteins of the invention are characterised in that they comprise a plant E2F DNA binding domain being of sequence of amino acid residues 146-206 of the plant E2F of SEQ ID No 6 or a functional variant thereof.
  • Particularly preferred target E2F binding domains in plant DNA are of sequence TTT(C/G)(C/G)(C/G)(C/G)(C/G), particularly TTT(C/G)(C/G)CG(C/G).
  • an isolated, enriched, cell free and/or recombinantly produced peptide or protein comprising SEQ ID No 4 Tyr Xaa Xaa Xaa Xaa Xaa Asp Xaa Xaa Xaa Xaa Xaa Asp Met Tip Glu or a functional variant thereof which lack other essential E2F peptide or protein regions, eg where it is a peptide of 16 to 100, more preferably 16 to 30 amino acids, it may be used to bind Rb and thus increase the effect of native E2F. More preferably the peptide consists of SEQ ID No 4 or a functional variant thereof.
  • the peptide is of SEQ ID No 2 but is modified such that the amino acid sequence SEQ ID No 4 is mutated such that its ability to bind Rb protein, eg. plant Rb protein, is increased or reduced from that of the native sequence of SEQ ID No 4 or abolished completely therefrom.
  • Rb protein eg. plant Rb protein
  • the peptide or protein is capable of acting as an E2F DNA binding, and optionally transcription activating, protein without being restricted by Rb binding. Such activity can then be more closely controlled using tissue specific or chemically inducible promoters
  • a third aspect of the present invention provides isolated, enriched, cell free and/or recombinant nucleic acid comprising a sequence encoding for expression of a peptide as described in the first aspect of the invention.
  • Preferred nucleic acids comprise DNA of less than 4,000 basepairs.
  • Preferred nucleic acids comprise only one peptide or protein encoding DNA sequence, optionally together with a reporter gene.
  • the nucleic acid is that encoding for a plant E2F or a functional variant thereof including SEQ ID No 3, eg. being that of SEQ ID No. 1.
  • Preferred nucleic acid comprises DNA or RNA of SEQ ID No 5 wherein when the nucleic acid is RNA the base T is substituted by U.
  • nucleic acid of SEQ ID No 5 has been deposited on 12 th May 1998 under the terms of the Budapest Treaty for the International Recognition of Microorganism Deposits for Patent Purposes of 28 th April 1977 at the Coleccion Espanola de Cultivos Tipo in plasmid pCLON35 under deposit number CECT5043. BamHI and Xhol, can be used to excise the insert cDNA from this. For in vitro transcription-translation, the full-length TmE2F cDNA was cloned into pBluescriptSK+ using these enzymes. It will be understood that nucleic acids of the invention may be double stranded DNAs or single stranded DNA of the cDNA or a sequence complementary thereto, eg. such as will have use as a probe.
  • Preferred nucleic acids are characterised in that they encode for a plant E2F or a functional variant thereof including SEQ ID No 3 or a sequence complementary thereto. Further preferred nucleic acids comprise DNA or RNA of SEQ ID No 5, whether double or single stranded, sense or a sequence complementary thereto. Preferred nucleic acids comprise a cDNA., for example comprising SEQ ID No 3 or 5. Such nucleic acids are optionally provided together with promoter, enhancer or stop sequences with no other gene coding regions. .
  • the DNA or RNA of the invention may have a sequence containing degenerate substitutions in the nucleotides of the codons in the sequences encoding for E2F proteins or peptides of the invention.
  • RNA U's replace the T's of DNA.
  • Preferred per se DNAs or RNAs are capable of hybridising with the polynucleotides encoding for peptides or proteins of the invention in conditions of low stringency, being preferably also capable of such hybridisation in conditions of high stringency.
  • condition of low stringency and “conditions of high stringency” are of course understood fully by those skilled in the art, but are conveniently exemplified in US 5202257, columns 9 and 10 and in WO 98/40483 on page 3; both of which are incorporated herein by reference.
  • the most preferred nucleic acids of the invention will hybridise at the most stringent conditions described in these patents while other embodiments will hybridise at the milder stringency or low stringency conditions.
  • an amino acid has a hydrophobic characterising group
  • a conservative substitution replaces it by another amino acid also having a hydrophobic characterising group; other such classes are those where the characterising group is hydrophilic, cationic, anionic or contains a thiol or thioether.
  • Such substitutions are only contemplated where the resultant protein has activity as an E2F peptide or protein as discussed with respect to DNA and Rb binding.
  • Nucleic acids of the invention may be degeneratively substituted with respect to that exemplified herein in the sequence listing.
  • the expression 'degeneratively substituted' refers to substitutions of nucleotides by those which result in codons encoding for the same amino acid; such degenerative substitutions being advantageous where the cell or vector expressing the protein is of such different type to the DNA source organism cell that it has different codon preferences for transcription/translation to that of the cDNA source cell. Such degenerative substitutions will thus be host specific.
  • DNA or RNA provided from a plant or the deposit referred to above may be altered by mutagenic means such as the use of mutagenic polymerase chain reaction primers.
  • Methods of producing the proteins or peptides of the invention characterised in that they comprise use of the DNA or RNA of the invention to express them from cells are also provided in this aspect.
  • nucleic acid probes or primers comprising a double or single stranded DNA of sequence corresponding to 10 or more contiguous nucleotides taken from the sequence SEQ ID No 5 are provided, with the proviso that they are not selected from those just encoding for the amino acid sequence that is relatively highly conserved with human E2F, ie.
  • probes and primers may be used in Northern and Southern blotting and in PCR, including RT-PCR, and LCR.
  • Oligonucleotides for use as probes conveniently comprise at least 18 contiguous bases of the sequences of the invention, preferably being of 30 to 100 bases long, but may be of any length up to the complete sequence or even longer.
  • the oligonucleotide preferably is of 10 to 20 bases long but may be longer. Primers should be single stranded but probes may be also be double stranded ie. including complementary sequences.
  • antisense DNA to any of the nucleic acids of the invention described above. This technique is well known in the art but is generally illustrated by US 5356799 and US 5107065 by way of example, each of which is incorporated herein by reference.
  • a fourth aspect of the invention provides a nucleic acid vector or construct comprising a nucleic acid of the present invention or comprising antisense nucleic acid thereto.
  • Suitable vectors or constructs for introducing the peptides or proteins of the invention into plants will occur to those skilled in the art of plant molecular biology, but are conveniently those discussed below with respect to methods for producing transgenic plants.
  • a fifth aspect of the present invention provides a plant cell comprising recombinant nucleic acid, preferably recombinant DNA, of the third aspect of the invention.
  • Nucleic acids of the invention are particularly provided in the form of such nucleic acid vectors or DNA construct comprising that nucleic acid or antisense nucleic acid sequence thereto.
  • a sixth aspect of the present invention provides a plant cell comprising antisense nucleic acid thereto capable of downregulating expression of native plant E2F.
  • a seventh aspect of the present invention comprises a transgenic plant or part thereof comprising recombinant nucleic acid, a vector or DNA construct as described above.
  • nucleic acid encoding them in situ.
  • Such method is conventionally carried out by incorporating oligonucleotides or polynucleotides, having sequences encoding the peptide or protein, into the plant cell DNA.
  • Such nucleotides can also be used to downregulate native E2F expression by gene silencing coexpression or through antisense strategy.
  • mutagenesis techniques eg. such as SDM
  • the nucleotides of the invention may be designed and produced to encode proteins and peptides which are functional variants or otherwise overactivated or inactivated, eg. with respect to binding, of the invention
  • Preferred plants of the seventh aspect may comprise the nucleic acid of the invention in a construct in functional association with promoter, activating or otherwise regulating sequences.
  • Preferred promoters may be tissue specific such that the resultant expression of peptide, and thus its effects, are localised to a desired tisssue. Promoters with a degree of tissue specificity will be known to those skilled in the art of plant molecular biology. Some of these are discussed below.
  • DNA, RNA and vector containing or encoding for these may be introduced into target cells in known fashion in the field of plant cell transformation. Particularly preferred is the method of introducing the DNA or RNA into pollen cells using techniques such as electroporation or gene gun technology.
  • tissue specific promoters, enhancers or other activators should be incorporated into the transgenic cells employed in operative relation with the DNA.
  • promotors may be active ectopically, continuously or may be inducible. It will be appreciated by those skilled in the art that inducible or tissue specific ie promotors will have advantage in so far as they are capable of providing alteration of the aforesaid E2F peptide or protein activity only when or where required, eg. at a particular stage of cell development or in a tissue such as leaves, roots, fruit or seeds or subparts thereof, eg. endosperm, that may be the subject of desired increase or decrease in size or even deletion. No particular limitation on the type of promoter to be employed is envisioned, although a reasonable amount of experimental trial may be expected to be undertaken to produce good results.
  • tissue specific and inducible promoters can be found in the following patent literature: US 5086169 (pollen specific), US 5459252 and US 5633363 (root specific), US 5097025 ((i)seed, (ii)mature plant), US 5589610 (stamen), US 5428146 (wound), US 5391725 ((i)chloroplast, (ii) cytosol), US 4886753 (root nodule), US 4710461 (pollen), US 5670349 (pathogen), US 5646333 (epidermis), US 5110732 ((i) root , (ii) radical), US 5859328 (pistil), US 5187267 (heat shock), US 5618988 (storage organ), US 5401836 and US 5792925 (root), US 4943674 (fruit), US 5689044 and US 5654414 (chemical), US 5495007 (phloem), US 5589583 (meristem), US 5824857 (vascul
  • Constitutive promoters will be well known to those skilled in the art and are discussed in the documents above and referred to below but for example include CaMv35S and alfalfa (MsH3gl) (see WO 97/20058 incorporated herein by reference).
  • transgenic plant any particular limitation on the type of transgenic plant to be provided is envisaged; all classes of plant, monocot or dicot, may be produced in transgenic form incorporating the nucleic acid of the invention such that E2F activity in the plant is altered, constituitively or ectopically.
  • the present inventors have provided antibodies capable of specifically biding with plant E2F factor peptides or proteins of the first aspect of the present invention, thus enabling the identification and isolation of further peptides and proteins of the invention and nucleic acid sequences encoding therefor, eg.. sing techniques such as Western blotting.
  • FIGURES. Fig. 1 DNA sequence of the wheat cDNA encoding E2F protein and deduced amino acid sequence.
  • Fig. 2 Northern analysis to identify mRNA encoding wheat E2F.
  • Fig. 3 Amino acid alignment of wheat E2F with human and Drosophila E2F proteins.
  • Fig. 4 Interaction between plant retinoblastoma protein (ZmRbl) and plant
  • E2F protein by yeast two-hybrid analysis.
  • Fig. 5 Domain organization of human E2F-1 and wheat E2F proteins.
  • the cDNA as well as an oligonucleotide derived from its 5' end were used to screen a wheat cDNA library by colony hybridization. Four positive clones, containing inserts of -2.0 kb, were recovered.
  • the sequence of the longest cDNA insert, shown in Figure 1, contains a single ORF of 1371 bp, with the potential to encode a protein of 458 amino acids. This ORF is flanked by 170 bp and 439 bp of 5' and 3' untranslated regions, respectively.
  • the plant Rb-interacting cDNA clone encodes a plant homologue of animal E2F.
  • Northern analysis indicated that a message, -2.0 kb in length, with the capacity to encode the entire TmE2F ORF, is present in RNA prepared from shoots and leaves, where most of the cells do not proliferate, as well as from root meristems and proliferating suspension cultured cells (Fig. 2). With the study presented here, we can not fully rule out the possibility that other, more distantly E2F-related genes, may exist. So far, Southern analysis strongly suggests that wheat E2F is the product of a single copy gene.
  • TmE2F cDNA clone encodes a plant E2F protein homologous to the animal counterparts is reinforced by analysis of the amino acid homology and domain organization of plant E2F.
  • plant E2F Based on a pairwise distance analysis, obtained with the CLUSTAL algorithm, plant E2F exhibits an overall -24.0- 27.5 % amino acid similarity with the subset formed by human E2F-1 (Helin et al, 1992; Kaelin et al., 1992: Shan et al., 1992), E2F-2 (Ivey-Hoyle et al, 1993; Lees et al., 1993) and E2F-3 (Lees et al., 1993), a slightly larger similarity (-25.0-29.8%) with E2F-4 (Beijersbergen et al., 1994; Ginsberg et al., 1994; Sardet et al, 1995) and E2F-5 (Sardet et al., 1995), and
  • Amino acid alignment of plant and animal E2F proteins revealed a similar domain organization and some specific characteristics of plant E2F.
  • the most conserved domain appears to be the DNA binding domain which is highly homologous among all members (Fig. 3). This domain includes a stretch of 15 amino acids (residues 182-196) fully conserved, which corresponds to one of the putative ⁇ helices of the conserved bHLH domain (Cress et al., 1993).
  • a significant degree of conservation between plant and animal E2F proteins was also found within the homo- and heterodimerization domains, including the characteristic leucine zipper motif (residues 219-240).
  • yeast two-hybrid analysis using several truncated proteins.
  • Human Rb and related proteins bind to E2F family members using their A7B pocket domain (Lees et al., 1993).
  • yeast cells were cotransformed with plasmids expressing the Gal4AD-E2F fusion protein and plasmids expressing the Gal4BD alone or fused to several truncated versions of plant Rb. Cells were grown on plates with and without histidine supplemented with 3-AT, as indicated in Fig. 4.
  • FIG. 5 A comparison of the domain organization of plant and human E2F proteins is shown in Fig. 5.
  • the DNA binding domain The DNA binding domain.
  • human E2F-1 was originally described as a basic helix-loop-helix (bHLH) protein (Cress et al., 1993).
  • the DNA binding domain of plant E2F (residues 146-209) is the most conserved region of the protein not only with mammalian E2F members but also with Drosophila E2F. Based on this high degree of conservation, one prediction is that plant E2F should bind to a DNA sequence very similar to the consensus human E2F-binding site (TTT(C/G)(C/G)CG(C/G); reviewed in Cobrinik, 1996).
  • E2F-consensus binding sequences have been found in the ribonucleotide reductase genes of Nicotiana tabacum (C. Gigot, personal communication).
  • E2F One striking feature of plant E2F is the low amino acid similarity of in the C- terminal region, which contains its Rb-binding motif, in relation to the high homology of other domains, e. g. the DNA-binding domain, among all animal E2Fs. It has been found that amino acids 409-426 in the C-terminal domain of human E2F-1, containing a relatively high proportion of acidic residues, are sufficient for binding to Rb and that point mutations within this short region drastically mofify the ability of human E2F-1 to associate with Rb (Cress et al, 1993, Helin et al., 1993).
  • E2F-1, -2 and -3 contains a short stretch of amino acids, absent in E2F-4, which act as a nuclear localization signal (NLS) and is related to that of c-myc (Dang and
  • Plant E2F does not contain such a consensus sequence. Therefore, we can speculate that plant E2F is translocated to the nucleus by other partner proteins.
  • NLS may be present in plant E2F.
  • the region of plant E2F encompassing residues 69 to 81 may behave as a
  • Plasmid pGBT-ZmRbl was constructed by cloning the ZmRbl cDNA (15) in frame to the Gal4 BD of pGBT8, pGBT-ZmRbl ⁇ C2(l-558) by deleting a Mscl-Xhol fragment of pGBT-ZmRbl and pGBT-ZmRbl ⁇ N ⁇ C2(69-558) by deleting a Mscl- Xhol fragment of pGBT-ZmRbl ⁇ N.
  • Plasmid pGBT-ZmRM ⁇ N(69-683) contains a N-terminal deletion of ZmRbl.
  • Plasmid pGADTmE2F(236-458) is a partial clone isolated in the screening and pGADTmE2F(236-373) was made by deleting a Sspl- Xhol fragment.
  • the full-length TmE2F cDNA was cloned into pBluescriptSK+.
  • yeast strain HF7c (MATa ura3-52 his3-200 ade2-101 lys2-801 trpl-901 leu2-3,112 gal4-542 gal80-538 LYS2::GALl ⁇ jAS-GALl ⁇ ATA-HIS3 URA3::GAL4 17mers(x3)-CyCl ⁇ ATA _ LacZ; Feilotter et al 1994, which contains the two reporter genes LacZ and HIS3, was used in the two-hybrid screening.
  • Yeasts were first transformed, with pGBTZmRbl, a plasmid containing the maize Rb protein (Xie et al., 1996) fused to the Gal4 DNA-binding domain (BD; TRPl marker) in the pGBT8 vector. Then, they were transformed with the pGAD-GH (AD; LEU2 marker) wheat cDNA library. The transformation mixture was plated on yeast drop-out selection media lacking tryptophan, leucine and histidine and supplemented with 5 mM and 10 mM 3-amino-l,2,4,triazole (3 -AT) to reduce the appearance of false positive growing colonies.
  • BD Gal4 DNA-binding domain
  • Transformants were routinely recovered during a 3 to 8 days period and were checked for growth in the presence of up to 20 mM 3 -AT. To corroborate the interaction between the two fusion proteins, ⁇ -galactosidase activity was assayed by a replica filter assay as described. Plasmid DNA was recovered from positive colonies by transforming into E. coli MH4, since this strain is leuB " , and its defect can be complemented by the LEU2 gene present in the pGAD-GH plasmid.
  • Triticum monococcum suspension culture P. M. Mullineaux; John Innes Centre, UK
  • Cells were synchronized with 10 mM hydroxyurea (HU) for 48 hours.
  • EXAMPLE 4 Production of antibodies specific for binding to plant E2F protein.
  • Polyclonal antibodies capable of specifically binding plant E2F protein were provided by producing a GST fusion with the 236-458 C-terminal fragment in Bluescript as described above. This was over-expressed in E.coli and purified on a Glutathione bead column. Rats were injected using standard immunisation protocols on day 1 and day 14 and serum derived from these used as polyclonal reagent. This serum was capable of use at 1/1000 dilution for Western Blotting purposes, (see standard procedures in Manual of Antibody Preparation. Coldspring Harbor Press).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Botany (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne un procédé de contrôle de la croissance des plantes et/ou de la réplication d'ADN cellulaire et/ou de la progression, différentiation et développement du cycle des cellules, ledit procédé consistant à accroître ou à réduire l'activité E2F dans les cellules des plantes.
PCT/EP1999/003158 1998-05-08 1999-05-07 Cellules de plantes transgeniques exprimant un peptide e2f vegetal recombinant WO1999058681A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU38280/99A AU3828099A (en) 1998-05-08 1999-05-07 Transgenic plant cells expressing a recombinant plant e2f peptide
JP2000548472A JP2002514423A (ja) 1998-05-08 1999-05-07 組換え植物ｅ２ｆペプチドを発現するトランスジェニック植物細胞
CA002327546A CA2327546A1 (fr) 1998-05-08 1999-05-07 Cellules de plantes transgeniques exprimant un peptide e2f vegetal recombinant
EP99920859A EP1084249A2 (fr) 1998-05-08 1999-05-07 Cellules de plantes transgeniques exprimant un peptide e2f vegetal recombinant

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ES9800975 1998-05-08
ESP9800975 1998-05-08
ESP9800981 1998-05-11
ES9800981 1998-05-11

Publications (2)

Publication Number Publication Date
WO1999058681A2 true WO1999058681A2 (fr) 1999-11-18
WO1999058681A3 WO1999058681A3 (fr) 1999-12-29

Family

ID=26155149

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/003158 WO1999058681A2 (fr) 1998-05-08 1999-05-07 Cellules de plantes transgeniques exprimant un peptide e2f vegetal recombinant

Country Status (5)

Country Link
EP (1) EP1084249A2 (fr)
JP (1) JP2002514423A (fr)
AU (1) AU3828099A (fr)
CA (1) CA2327546A1 (fr)
WO (1) WO1999058681A2 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000056905A3 (fr) * 1999-03-19 2000-12-28 Cropdesign Nv Procede pour accelerer et/ou ameliorer la croissance et/ou le rendement de vegetaux ou pour modifier leur architecture
WO2001023531A1 (fr) * 1999-09-24 2001-04-05 Luminis Pty Ltd Reconnaissance de differences de structure de cycle cellulaire entre cellules embryonnaires et cellules differenciees
WO2003025185A1 (fr) * 2001-09-14 2003-03-27 Cropdesign N.V. Procede destine a modifier le nombre de cellules, l'architecture et le rendement de plantes par surexpression du facteur de transcription de e2f
WO2003018818A3 (fr) * 2001-08-24 2003-09-04 Cropdesign Nv Procede et moyens de modulation des proteines du cycle cellulaire de plantes et leur utilisation pour reguler la croissance cellulaire de plantes
US7888460B2 (en) 1999-10-01 2011-02-15 Isis Innovation Limited Diagnostic and therapeutic epitope, and transgenic plant
US20110159486A1 (en) * 2009-12-31 2011-06-30 Pioneer Hi-Bred International, Inc. Cell cycle switch 52(ccs52) and methods for increasing yield
US9017690B2 (en) 2004-04-28 2015-04-28 Btg International Limited Epitopes related to coeliac disease
US10053497B2 (en) 2002-06-05 2018-08-21 Oxford University Innovation Limited Therapeutic epitopes and uses thereof
US10105437B2 (en) 2004-04-28 2018-10-23 Btg International Limited Epitopes related to coeliac disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997047647A1 (fr) * 1996-06-13 1997-12-18 Consejo Superior De Investigaciones Cientificas Proteines vegetales

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000056905A3 (fr) * 1999-03-19 2000-12-28 Cropdesign Nv Procede pour accelerer et/ou ameliorer la croissance et/ou le rendement de vegetaux ou pour modifier leur architecture
WO2001023531A1 (fr) * 1999-09-24 2001-04-05 Luminis Pty Ltd Reconnaissance de differences de structure de cycle cellulaire entre cellules embryonnaires et cellules differenciees
US7888460B2 (en) 1999-10-01 2011-02-15 Isis Innovation Limited Diagnostic and therapeutic epitope, and transgenic plant
US8329144B2 (en) 1999-10-01 2012-12-11 Isis Innovation Limited Diagnostic and therapeutic epitope, and transgenic plant
WO2003018818A3 (fr) * 2001-08-24 2003-09-04 Cropdesign Nv Procede et moyens de modulation des proteines du cycle cellulaire de plantes et leur utilisation pour reguler la croissance cellulaire de plantes
WO2003025185A1 (fr) * 2001-09-14 2003-03-27 Cropdesign N.V. Procede destine a modifier le nombre de cellules, l'architecture et le rendement de plantes par surexpression du facteur de transcription de e2f
US7592507B2 (en) 2001-09-14 2009-09-22 Croodesign, N.V. Method to modify cell number, architecture and yield of plants by overexpressing the E2F transcription factor
US10053497B2 (en) 2002-06-05 2018-08-21 Oxford University Innovation Limited Therapeutic epitopes and uses thereof
US9017690B2 (en) 2004-04-28 2015-04-28 Btg International Limited Epitopes related to coeliac disease
US10105437B2 (en) 2004-04-28 2018-10-23 Btg International Limited Epitopes related to coeliac disease
US20110159486A1 (en) * 2009-12-31 2011-06-30 Pioneer Hi-Bred International, Inc. Cell cycle switch 52(ccs52) and methods for increasing yield

Also Published As

Publication number Publication date
AU3828099A (en) 1999-11-29
CA2327546A1 (fr) 1999-11-18
WO1999058681A3 (fr) 1999-12-29
EP1084249A2 (fr) 2001-03-21
JP2002514423A (ja) 2002-05-21

Similar Documents

Publication Publication Date Title
Feldbrügge et al. PcMYB1, a novel plant protein containing a DNA‐binding domain with one MYB repeat, interacts in vivo with a light‐regulatory promoter unit
Abe et al. Role of arabidopsis MYC and MYB homologs in drought-and abscisic acid-regulated gene expression.
Xie et al. GRAB proteins, novel members of the NAC domain family, isolated by their interaction with a geminivirus protein
Meijer et al. Transcriptional repression by Oshox1, a novel homeodomain leucine zipper protein from rice
US5929305A (en) Plant material containing non-naturally introduced binding protein for regulating cold and dehydration regulatory genes
Lopato et al. A novel family of plant splicing factors with a Zn knuckle motif: examination of RNA binding and splicing activities
USRE44266E1 (en) Expression of eukaryotic polypeptides in chloroplasts
Pattanaik et al. The interaction domains of the plant Myc-like bHLH transcription factors can regulate the transactivation strength
US10982218B2 (en) Strong activation domain
CN112010955B (zh) 小麦抗赤霉病相关蛋白TaRBL及其编码基因与应用
CN107827964A (zh) 一种与植物耐逆性相关的转录因子PwNAC2及其编码基因与应用
US20040123349A1 (en) SINAT5, an Arabidopsis thaliana gene promotes ubiquitin related degradation
CN1431309B (zh) 编码植物转录因子的基因
WO1999058681A2 (fr) Cellules de plantes transgeniques exprimant un peptide e2f vegetal recombinant
WO1997047745A1 (fr) Proteines vegetales associees au retinoblastome
CN104220596A (zh) 对环境应力显示出提高的耐性的植物体及其制造方法
EP1214436A2 (fr) Proteines du reactif associe de dimerisation (dp) du ble et utilisations correspondantes
Zhou et al. Molecular cloning of a small DNA binding protein with specificity for a tissue-specific negative element within the rps 1 promoter
JP2002506345A (ja) 植物ｇｒａｂタンパク質
CN110878316A (zh) 一种旱金莲调控芥酸合成基因及其应用
Kawata et al. Isolation and characterization of a cDNA clone encoding the TATA box-binding protein (TFIID) from wheat
CN102234321B (zh) 植物耐逆性相关蛋白GmNF-YB1及其编码基因和应用
US5362864A (en) Trans-activating factor-1
US20020184659A1 (en) Plant genes encoding Dr1 and DRAP1, a global repressor complex of transcription
CN110387377B (zh) 油菜耐旱基因BnNAC129及其用于制备耐旱转基因植物的应用

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 1999920859

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09674361

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2327546

Country of ref document: CA

Ref country code: CA

Ref document number: 2327546

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

WWP Wipo information: published in national office

Ref document number: 1999920859

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1999920859

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载